Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
CARLSBAD, Calif. - Palisade Bio, Inc. (NASDAQ:PALI), a micro-cap biotech company with a market capitalization of $5.08 million, announced Thursday that China’s National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the company’s phosphodiesterase-4 B/D inhibitor being developed for fibrostenotic Crohn’s disease and ulcerative colitis. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 2.84.
The patent, titled "Gut Microbiota-Activated PDE4 Inhibitor Prodrug," will cover composition of matter claims for PALI-2108 in China with protection extending into 2045, subject to potential extensions related to regulatory approval timelines.
"Strengthening the global intellectual property portfolio around PALI-2108 remains a priority as we continue advancing this first-in-class therapy," said J.D. Finley, Chief Executive Officer of Palisade Bio, according to the press release.
PALI-2108 is currently being evaluated in a Phase 1b/2a clinical trial for the treatment of fibrostenotic Crohn’s disease and ulcerative colitis. The drug is designed to target the terminal ileum and colon specifically.
The company describes PALI-2108 as the first and only PDE4 inhibitor designed with this specific targeting mechanism for these conditions. Inflammatory bowel disease represents a growing market opportunity in China, with industry forecasts approaching $1 billion in total revenues by 2030, according to information provided in the company statement.
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases. The company expects multiple clinical milestones and data readouts in the next 12-18 months.
In other recent news, Palisade Bio announced positive topline results from its Phase 1 studies of PALI-2108, which is being developed to treat fibrostenotic Crohn’s disease and moderate to severe ulcerative colitis. The trials met their primary endpoints, demonstrating safety, tolerability, and favorable pharmacokinetics, with no serious adverse events reported. Additionally, Palisade Bio presented promising preclinical data for PALI-2108 at Digestive Disease Week, highlighting its potential efficacy in treating ulcerative colitis. The study showed that the drug effectively reduced certain inflammatory markers in a mouse model, suggesting it could alleviate symptoms associated with the disease. Furthermore, Palisade Bio has appointed Emil Chuang to its Board of Directors. Dr. Chuang brings extensive experience in drug development, having contributed to the regulatory approvals of treatments for pediatric Crohn’s disease and morbid obesity. These developments mark significant steps forward for Palisade Bio in its ongoing research and leadership strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.